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TGF-β1Renal ischemia/reperfusion (I/R) injury is the most common cause of acute kidney injury, having a high rate of
mortality and no effective therapy currently available. Apelin-13, a bioactive peptide, has been shown to inhibit
the early lesions of diabetic nephropathy in several mouse models by us and others. To test whether apelin-13
protects against renal I/R induced injury, male rats were exposed to renal I/R injury with or without apelin-13
treatment for 3 days. Apelin-13 treatment markedly reduced the injury-induced tubular lesions, renal cell apo-
ptosis, and normalized the injury induced renal dysfunction. Apelin-13 treatment inhibited the injury-induced
elevation of inﬂammatory factors and Tgf-β1, as well as apoptosis. Apelin-13 treatment also inhibited the
injury-induced elevation of histonemethylation and Kmt2d, a histonemethyltransferase of H3K4me2, following
renal I/R injury. Furthermore, in cultured renal mesangial and tubular cells, apelin-13 suppressed the injury-
induced elevation of Tgf-β1, apoptosis, H3K4me2 and Kmt2d under the in vitro hypoxia/reperfusion (H/R) condi-
tions. Consistently, over-expression of apelin signiﬁcantly inhibited H/R-induced elevation of TGF-β1, apoptosis,
H3K4me2 andKmt2d. The present study therefore suggests apelin-13may be a therapeutic candidate for treating
acute kidney injury.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Renal ischemia/reperfusion (I/R) injury is the most common cause of
acute kidney injury (AKI) after major surgery or renal transplantation in
both allograft and native kidneys [1]. AKI affects 5% of all hospitalized pa-
tients with an unacceptably high rate of mortality [2]. AKI always implies
a poor prognosis with no effective therapy currently available [3]. Renal I/
R injury usually causes primary tubular epithelial cell injury, including tu-
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R injury also occur, which lead to mesangial contraction and cessation
of glomerular ﬁltration. Thus, the interaction of microvascular (including
glomerular and medullary parts) and tubular events both contribute to
the pathogenesis of acute ischemic renal failure [4,5]. Although renal I/R
injury has been extensively studied, the pathophysiologic process involv-
ing inﬂammation and cell apoptosis, as well as its relationship to the sub-
sequent renal injury, remain to be fully elucidated.
TGF-β1 (transforming growth factor-β1), a key member of TGF
super-family, has been established as the central mediator of renal ﬁ-
brosis and inﬂammation associated with multiple progressive kidney
diseases [6,7]. Fibrosis represents the ﬁnal step of renal injury which
ultimately leads to end-stage kidney failure [8], therefore, blocking
TGF-β1 is an attractive approach to prevent renal injury.
Histonemodiﬁcations, including acetylation, methylation and phos-
phorylation, play important roles in the regulation of transcriptional
activity [9–12]. Histone acetylation, which is mediated by histone ace-
tyltransferases (HATs) and histone deacetylases (HDACs), regulates
chromatin structure and controls genes expression [13]. Recent studies
have shown that changes in the levels of HDACs are associated with
renal I/R injury [14,15]. In addition, histone methyltransferases
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chromatin remodeling and gene expression [16]. However, the roles of
histone methylation or enzymes that regulate histone methylation in
the pathogenesis of acute renal I/R injury remain unknown.
The apelin family of adipokines is derived from a 77-residue pre-
proprotein with lengths varying from 12 to 36 residues [17,18].
Apelin-13, the most active member of the apelin group, has multiple
biological functions including regulation of glucose balance, blood
pressure, cardiovascular functions, blood vessel integrity and renal
function [19–24]. APJ (angiotensin I receptor-related protein J receptor),
which belongs to GPCR (G-protein-coupled receptor) family, is the only
endogenous receptor for apelin. Apelin and APJ are widely expressed in
a variety of tissues like kidney, adipose, brain and lung [25,26]. Several
animal models indicate that the apelin–APJ system plays a critical role
in the regulation of cardiovascular ﬂuid homeostasis [27,28]. The
apelinergic system (apelin and its receptor APJ) has also been suggested
to be a promising therapeutic target in obesity-associated insulin resis-
tance [29].
Recently, we and others demonstrated that administration of apelin-
13 reduces kidney and glomerular hypertrophy as well as renal inﬂam-
mation in type 1 diabetic mice [24,30], which makes apelin-13 a good
candidate for treating diabetic nephropathy [31]. Based on this ﬁnding,
we wondered whether apelin-13 might also have beneﬁcial effects on
acute renal injury, such as renal I/R injury. In the present study, we ad-
ministered apelin-13 to renal I/R injured rats. The injury-induced tubu-
lar lesions, renal dysfunction, renal cell apoptosis, alterations in histone
methylation and histonemethyltransferase/demethylase, as well as the
levels of Tgf-β1were analyzed. In addition, in vitro hypoxia/reperfusion
(H/R) injury was performed on cultured renal mesangial cells and
tubular cells, and the effects of administering apelin-13 and apelin
over-expression on the injury-induced apoptosis, elevation of Tgf-β1,
alterations in histone methylation and HMTs/HDMs were assessed.
Apelin-13 was found to suppress renal inﬂammation and apoptosis in
both I/R or H/R injury by inhibiting Tgf-β1. These results suggest that
apelin-13 should be considered as a new therapeutic target for the
treatment of AKI.
2. Materials and methods
2.1. Animals and renal ischemia/reperfusion (I/R) model
Male Wistar rats were obtained from the Hubei Animal Laboratory,
and housed in ventilated microisolator cages with free access to water
and food. Rats weighing 180 ± 20 g were used and assigned to one of
the following groups: CT group, uninjured rats with vehicle administra-
tion; I/R group, rats underwent I/R injury with vehicle administration;
I/R+Ap group, rats underwent I/R injurywith 5 μg/kg BWapelin-13 ad-
ministered twice per day. Apelin-13was chemically synthesized by stan-
dard Fmoc strategy and puriﬁed to N98% with rp-HPLC as we previously
described [32,33]. I/R injury was performed as previously described [34].
Brieﬂy, rats were anesthetized and underwent midline abdominal inci-
sions with their left renal pedicle bluntly clamped by a clamp for 30
min (unilateral renal occlusion). After removing the clamps, wounds
were sutured and the animals were allowed to recover for 3 days before
sacriﬁce. Control animals were sham operated. All animal experiments
were approved by the Committee on Ethics in the Care and Use of
Laboratory Animals of the College of Life Sciences, Wuhan University.
2.2. Assessment of renal function
Twenty-four-hour urine samples were collected in metabolic cages
1 day before sacriﬁce. Urine levels of creatinine and total protein were
measured with an Olympus AU2700 automatic biochemistry analyzer
using a creatinine reagent kit (Fuxing Changzheng Medical Inc.,
Shanghai, China) or a total protein reagent kit (Greatwall Clinical
Reagent Inc., Baoding, China) as we previously described [24].2.3. Renal histology
Renal sections were stained with hematoxylin and eosin (H&E). Hall-
marks of acute tubular necrosis (ATN) were examined on a double-blind
basis. The degree of renal damagewas semi-quantitatively evaluatedwith
a scale in which 0 represents no abnormalities, and 1+, 2+, 3+, 4+
stand for slight (up to 20%), moderate (20 to 40%), severe (40 to 60%),
and total necrosis (affecting more than 80% of renal parenchyma),
respectively [35].2.4. TUNEL assay
Parafﬁn-embedded sections were deparafﬁnized and rehydrated as
previously reported [24]. Apoptotic cells were detected by TUNEL
assay using an In Situ Cell Death Detection Kit (Roche, Mannheim,
Germany) as previously described [36]. At least six different areas per
renal sample of TUNEL positive cells were counted using an Olympus
BX60 microscope equipped with a digital CCD and reported as number
of TUNEL-positive nuclei divided by the total number of cells per ﬁeld.2.5. Cell culture and in vitro H/R injury
HBZY-1 (a rat mesangial cell line) and NRK-52E (a rat tubular epi-
thelia cell line) were cultured in DMEM media (Hyclone, South Logan,
USA) with 5.5 mM glucose plus 5% fetal bovine serum (FBS) (Gibco,
Grand Island, USA), andmaintained in a 37 °C incubator (Thermo scien-
tiﬁc, Marietta, USA) with humidiﬁed atmosphere of 21% O2 which was
regarded as the normal culture condition. In vitro H/R experiments
were performed as previously described with slight modiﬁcations
[37]. At 80% conﬂuence, cells were put into a 37 °C incubator under 1%
O2 with the normal media replaced with media lacking glucose and
FBS, which was regarded as hypoxia. After culturing under the hypoxia
condition for a speciﬁed amount of time (4 hrs for HBZY-1 cells and 1 hr
for NRK-52E cells), cells were returned to the normal culture condition
for two hours, which was regarded as reperfusion. For apelin-13 treat-
ment, 300 pM apelin-13 was added to media during the hypoxia and
reperfusion period as in our previous report [24]. 2-TCP (trans-2-
Phenylcyclopropylamine hydrochloride), a HDM inhibitor [38], was
added to media to induce the total methylation of H3K4 in the cultured
renal cells.2.6. Transfection
HBZY-1 cells were plated in six-well plates and transfected the
next day with either pPCAGSIH-β-gal or pPCAGSIH-apelin plasmids
(kind gifts from Dr. Takakura, Osaka University) using Fugene HD
transfection reagent (Promega, Madison, USA) according to the
manufacturer's instruction.2.7. Western blots
Freshly collected kidney or cultured cells were sonicated in ice-cold
RIPA buffer (Beyotime, Haimen, China) and protein concentrations
were quantitated as previously described [39]. 20–80 μg of protein
from each sample were separated by SDS-PAGE. The proteins were
transferred onto PVDF membranes for immunodetection. The list of an-
tibodies used in the present study is provided in Supplementary
Table S1. The intensity of the targeted protein bands was evaluated
using Quantity One 1-D Analysis Software. Individual protein levels
were quantitated relative to the β-actin level in the same sample and
further normalized to the respective control group, which was set
at one.
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Total RNA was isolated from kidneys or cultured cells using RNAiso
Plus (TaKaRa Biotechnology, Dalian, China). Total RNA was reverse
transcribed into cDNA using M-MLV ﬁrst strand synthesis system
(Invitrogen, Grand Island, USA). The abundance of speciﬁc gene tran-
scripts was assessed by PCR. The sequences of the primers used are
listed in Supplementary Table S2. PCR products were separated by elec-
trophoresis using 1.5% agarose gels, and images were photographed
using a Molecular Imager Gel Doc XR (Bio-Rad, Hercules, USA). Band
density was quantiﬁed using Quantity One 1-D Analysis Software
(Bio-Rad). The mRNA level of the targeted gene was quantitated ﬁrst
against the Rn18s level from the same sample, then normalized to the
non-injured group or the cells transferred with pPCAGSIH-β-gal under
normal conditions, which was set at one.
2.9. Chromatin immunoprecipitation (ChIP) assay
Kidneys were cross-linked with 1% formaldehyde for 10 min and a
ChIP assay was performed as previously described [24]. Chromatin
was immunoprecipitated with an anti-H3K4me2 antibody (Abcam,
Cambridge, UK). The puriﬁed DNA was detected by PCR. The primer
sequences used are provided in supplementary Table S1. The input sam-
ples were used as an internal control for comparison between samples.
2.10. Statistical analysis
The data were expressed as mean ± standard error of the mean
(SEM). Statistical signiﬁcance was determined by analyzing the data
with the nonparametric Kruskal–Wallis test, followed by the Mann–
Whitney test. Differences were considered statistically signiﬁcant at
P b 0.05.
3. Results
3.1. Apelin-13 protects against renal I/R injury induced morphological and
functional changes
The effects of different dosages of apelin-13 (1, 2, 5 and 10 μg/kg
BW) on the renal morphological changes were ﬁrst examined at
3 days after I/R injury (Fig. S1). Compared to non-injured kidneys, I/R in-
jury led to severe tubular damage, as evidenced by widespread tubularFig. 1.Apelin-13 treatment inhibits I/R injury induced renal dysfunction. RepresentativeHE stain
tal groups. (C) Urine volume in different experimental groups. (D) Proteinuria in different exp
non-injured rats; I/R, I/R injured rats; I/R + Ap, apelin-13 treated I/R injured rats, n = 5–7 per
bular necrosis. ⁎p b 0.05 compared to CT rats; #p b 0.05 compared to I/R injured rats.necrosis, cast formation and tubular cells denudation (Figs. 1A and S1).
Histochemistry results demonstrated that administration of 5 and
10 μg/kg BW of apelin-13 has protective effects on renal morphology,
while lower doses (1 or 2 μg/kg BW) showed no obvious beneﬁcial
effects on renal morphology after the I/R injury (Fig. S1). Semi-
quantitative results demonstrated that a 5 μg/kg apelin-13 treatment
signiﬁcantly improved the pathological scores in the injured kidneys
(Fig. 1B); this dose was thus chosen for further in vivo experiments.
Kidney damagewas assessed bymeasurement of 24-hurine volume,
proteinuria and urine creatinine. Functional renal studies demonstrated
that renal I/R injury caused kidney dysfunction, as reﬂected by signiﬁ-
cantly elevated 24-h urine volume, proteinuria and urine creatinine
(Fig. 1C–E); whereas apelin-13 treatment suppressed I/R injury-
induced elevation of these renal function parameters (Fig. 1C–E).
However, the calculated ratio of protein/creatinine in different experi-
ment groups suggested that 3 days after I/R-injury, there was no in-
crease in the protein/creatinine ratio, nor did apelin show any effect
on this ratio (Supplementary Fig. S2).
3.2. Apelin-13 normalizes I/R or H/R injury induced down-regulation of
Apln mRNA level in vivo and in vitro
The endogenous AplnmRNA level was examined in different exper-
imental groups. As expected, the mRNA level of Apln was signiﬁcantly
decreased in the kidney after I/R injury, while this injury-induced de-
crease was largely prevented by administration of apelin-13 (Fig. 2A).
At the same time, the protein level of APJ, the endogenous receptor for
apelin, was similar among experimental groups. Hypoxia inducible fac-
tor 1α (Hif1α), a key factor involved in the cellular and systemic re-
sponses to hypoxia, has been demonstrated to contribute to the
pathogenesis of I/R injury [40]. The protein level of Hif1αwas increased
in the kidneys after I/R injury, whereas administration of apelin-13 sig-
niﬁcantly reduced I/R injury-induced up-regulation of Hif1α (Fig. 2B).
Two different renal cell lines were used to evaluate the effects of
apelin-13 treatment under in vitro H/R condition. A known hypoxia
sensor, the levels of Hif1αmarkedly increased after H/R injury in both
NRK-52E cells andHBZY-1 cells (Fig. 2D and F), indicating the successful
establishment of hypoxic injury in these cells. In NRK-52E cells, H/R led
to a signiﬁcant decrease in Apln mRNA level. The injury-induced de-
crease in Apln mRNA was signiﬁcantly reduced by administrating
apelin-13 to the injured renal tubular epithelial cells (Fig. 2C). There
was no signiﬁcant change in the APJ protein level among theing pictures (A) and quantitative results of renal damage score (B) in different experimen-
erimental groups. (E) Urine creatinine concentration in different experimental groups. CT,
group. § indicates vast formation; arrow indicates tubular cells denudation; € indicates tu-
Fig. 2. Apelin-13 normalized I/R or H/R injury induced downregulation of AplnmRNA level and Hif1α overexpression in kidneys, cultured renal cells. Representative PCR analysis with
densitometric quantitative results of Apln, Rn18s were shown in (A, C, E). Representative Western blot analysis with densitometric quantitative results of APJ, Hif1α and β-actin were
shown in (B, D, F). CT or NC, non-injured rats or cells; I/R or H/R, I/R injured rats or H/R injured cells; I/R or H/R + Ap, apelin-13 treated I/R injured rats or H/R injured cells, n = 3–5
per group. ⁎p b 0.05 compared to CT or NC group; #p b 0.05 compared to I/R or H/R group.
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cells, the AplnmRNA level was also signiﬁcantly decreased under a H/R
condition, which was markedly up-regulated by apelin-13 treatment in
the injured HBZY-1 cells (Fig. 2E). There was no signiﬁcant difference in
the APJ expression level between the untreated and H/R stimulated
cells, however, 300 pM apelin-13 treatment signiﬁcantly increased the
APJ level in HBZY-1 cells after H/R stimulation (Fig. 2F). Furthermore,
apelin-13 treatment normalized the injury-induced elevation of Hif1α
level in both cell lines (Fig. 2D and F).
3.3. Apelin-13 suppresses I/R or H/R injury induced inﬂammation and
apoptosis in kidneys and cultured renal cells
Up-regulation of inﬂammatory chemokines and adhesionmolecules
in the injured sites causes inﬂammatory cells to inﬁltrate, which in turn
ampliﬁes I/R injury [41,42]. We observed that the level of MCP-1, an in-
ﬂammatory chemokine, and the level of ICAM-1, an adhesion molecule,
were both signiﬁcantly induced in the kidneys after renal I/R injury.
Apelin-13 treatment signiﬁcantly reduced the injury-induced up-
regulation of ICAM-1 and MCP-1 in the kidneys (Fig. 3A).
Cleavage of caspase-3 and caspase-8 activates these two caspases
and represents the execution stage of cell death [14,43]. Compared to
the non-injured kidneys, elevation of the cleaved, active forms of
caspase-3 and caspase-8 were found in the kidneys of I/R injured rats.
Administration of apelin-13 markedly attenuated such injury-induced
activation of caspases (Fig. 3B). The activation of caspase-12 after
renal I/R injury was also reported in a previous study [44]. Compared
to the non-injured kidneys, there was a trend toward elevation of
cleaved forms of caspase-12 in the kidneys of I/R injured rats, while ad-
ministration of apelin-13 signiﬁcantly inhibited the cleavage of caspase-
12 compared to the I/R-injury per se (Fig. 3B). To further determine
whether apelin-13 treatment inhibits I/R injury-induced apoptosis in
the kidneys, a TUNEL assay was performed. Substantially increased
numbers of TUNEL+ cells were evident in renal tubular cells after theinjury, while apelin-13 treatment signiﬁcantly abrogated such injury-
induced increase in cell death (Fig. 3C).
Consistent with the in vivo studies, the levels of the active, cleaved
forms of caspase-3 and caspase-8 were also signiﬁcantly increased in
NRK-52E cells in the H/R injury model (Fig. 3D). Apelin-13 treatment
markedly suppressed H/R stimulated activation of cell death (caspase-8
and caspase-3) in cultured renal tubular epithelial cells (Fig. 3D). Consis-
tentwith the results ofNRK-52E cells, the levels of active, cleaved formsof
caspase-3, caspase-8 and caspase-12 were also signiﬁcantly increased
in HBZY-1 cells following H/R injury (Fig. 3E). Apelin-13 treatment
markedly suppressedH/R stimulated activation of cell death in cultured
mesangial cells (Fig. 3E).
3.4. Apelin-13 normalizes I/R or H/R injury induced alteration in histone
modiﬁcations in kidneys and cultured renal cells
We previously demonstrated that histone acetylation is involved in
the pathogenesis of diabetic nephropathy [24], in this study, we sought
to determine whether histone acetylation has similar effects on I/R in-
jured kidneys. The changes in histone acetylation after renal I/R injury
were investigated. The levels of ac-K, ac-H3K9, ac-H3K18, ac-H3K23,
ac-H3K56 and ac-H4K8 were signiﬁcantly increased in the kidneys
after I/R injury compared to those in the non-injured kidneys (Fig. S3).
Apelin-13 treatment markedly suppressed I/R injury-induced increases
in the levels of ac-K, ac-H3K23 and ac-H3K56 in the kidneys, and
showed no signiﬁcant effects on other histone acetylation sites
(Fig. S3). However, no signiﬁcant change to ac-Kwas found in H/R stim-
ulated HBZY-1 and NRK-52E cells (data not shown).
Furthermore, the levels of several histone methylation sites were
examined. There were dramatic increases in the levels of H3K4me2
(4.7-fold), H3K9me3 (2.2-fold), H3K79me1 (5.9-fold) in the kidneys
after I/R injury (Fig. 4A). On the other hand, the level of H4K20me3
was decreased in the I/R injury group (Fig. 4A), whereas the levels of
H3K4me1 and H3K4me3 were not signiﬁcantly changed in the kidneys
Fig. 3. Apelin-13 suppresses I/R or H/R injury induced inﬂammation and apoptosis in kidneys, cultured renal cells. Representative Western blot analysis with densitometric quantitative
results of MCP-1, ICAM-1 and β-actin were shown in (A). Representative Western blot analysis with densitometric quantitative results of caspase-3 (35 KD), c-cas3 (19 KD), c-cas3 (17
KD), c-cas8 (26KD), c-cas8 (18KD), caspase12 (42 KD), c-cas12 (38 KD), and β-actin are shown in (B, D and E). (C) Representative TUNEL stained pictures for different experimental
groups. Top panels, DAPI staining (blue color); bottom panels, TUNEL staining (green color). CT or NC, non-injured rats or cells; I/R or H/R, I/R injured rats or H/R injured cells; I/R or
H/R + Ap, apelin-13 treated I/R injured rats or H/R injured cells, n = 3–7 per group. ⁎p b 0.05 compared to CT or NC group; #p b 0.05 compared to I/R or H/R group.
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levels of H3K4me2 and H3K79me1 after I/R injury (Fig. 4A). The
mRNA level of several HMTs (Ash1, Kmt2d, Set7/9, Set1, Dot1l) and
HDMs (Kdm1a, Kdm5a) were further examined. Signiﬁcant increases
in the levels of Ash1, Kmt2d, Set7/9 and Dot1lwere observed in the kid-
neys of I/R injured rats compared with those in the non-injured rats.
Apelin-13 treatment suppressed I/R injury-induced up-regulation of
Ash1, Kmt2d and Set7/9, but showed no effect on the level of Dot1l in
the kidneys (Fig. 4B). There were no signiﬁcant changes in the mRNA
level of Set1, Kdm1a and Kdm5a among experimental groups (Fig. 4B).
Furthermore, an immunochemical study of renal sections demonstrated
that the level of Kmt2d was increased in renal tubules and glomeruli
after I/R injury, and administration of apelin-13 signiﬁcantly inhibited
the injury-induced elevation of Kmt2d (Fig. 4C).
To further conﬁrm the in vivo ﬁnding that apelin-13 mediates his-
tone methylation, we analyzed the levels of H3K4me2 and H3K79me1in the NRK-52E cells cultured under normal or H/R conditions. The
levels of H3K4me2 and H3K79me1 were markedly increased in renal
tubular epithelial cells cultured under H/R condition compared to
those in control cells, whereas apelin-13 treatment only signiﬁcantly
abrogated the H/R-induced up-regulation of H3K4me2 (Fig. 4D). More-
over, substantial increases in H3K4me2 and H3K79me1were evident in
HBZY-1 cells cultured under H/R condition comparedwith those in con-
trols, and such increaseswere reversed by apelin-13 treatment (Fig. 4F).
Moreover, NRK-52E cells cultured under H/R condition showed a signif-
icant increase in Kmt2d mRNA compared to control cells. Apelin-13
treatment signiﬁcantly suppressed H/R induced increase of Kmt2d
mRNA in NRK-52E cells (Fig. 4E). In addition, signiﬁcant increases in
Ash and Kmt2d mRNA with no change in Set7/9 mRNA were found
after H/R in the HBZY-1 cells, whereas apelin-13 treatment of HBZY-1
cells signiﬁcantly suppressed the H/R-induced increase of Kmt2d
mRNA, but not AshmRNA (Fig. 4G).
Fig. 4. Apelin-13 suppresses I/R or H/R injury induced histone hypermethylation and in the kidneys, cultured renal cells. RepresentativeWestern blot analysis with quantitative densito-
metric results of H3K4me1, H3K4me2, H3K4me3, H3K9me3, H4K20me3, H3K79me1 and H3 are shown in (A). Representative PCR analysis with densitometric quantitative results of
Ash1, Kmt2d, Set7/9, Set1, Dot1l, Kdm1a, Kdm5a and Rn18s were shown in (B). (C) Representative Kmt2d staining pictures for different experimental groups. Representative Western
blot analysis with densitometric quantitative results of H3K4me2, H3K79me1 and H3 were shown in (D and F). Representative PCR analysis with densitometric quantitative results of
Ash1, Kmt2d, Set7/9, and Rn18swere shown in (E and G). CT or NC, non-injured rats or cells; I/R or H/R, I/R injured rats or H/R injured cells; I/R or H/R + Ap, apelin-13 treated I/R injured
rats or H/R injured cells, n = 3–7 per group. ⁎p b 0.05 compared to CT or NC group; #p b 0.05 compared to I/R or H/R group.
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tion, per se, in the cultured renal cells can induce cell injury or not, TCP,
an inhibitor of HDM [38], was used to treat NRK-52E cells. Compared to
DMSO treated cells, TCP induced signiﬁcant increases in H3K4 methyla-
tion in a dose-dependent manner (supplementary data, Fig S4). At the
same time, the activation of caspase-8 and caspase-3, as well as the
level of ICAM-1 were also dose-dependently induced by TCP treatment
in NRK-52E cells (supplementary data, Fig. S4), indicating that apoptosis
and inﬂammation might be induced by elevation of H3K4 methylation.3.5. Apelin-13 inhibits I/R or H/R injury induced up-regulation of Tgf-β1
TGF-β1 has long been implicated as a centralmediator of tissue scar-
ring, apoptosis and ﬁbrosis in many disease models, including acute
renal injury [45]. Signiﬁcantly increased Tgf-β1 mRNA was evident in
the kidneys after I/R injury, and apelin-13 treatment signiﬁcantly re-
duced I/R-induced up-regulation of Tgf-β1 in the kidneys (Fig. 5A). A
ChIP assay further demonstrated increased recruitment of H3K4me2
to the promoter of Tgf-β1, which was consistent with the increased
Fig. 5. Apelin-13 inhibits I/R or H/R injury induced Tgf-β1 in kidneys and cultured renal
cells. Representative PCR analysis with densitometric quantitative results of Tgf-β1
and Rn18s are shown in (A, C, D). (B) Quantitative analysis of PCR of chromatin
immunoprecipitated DNA, which measures the binding afﬁnity of H3K4me2 to the pro-
moter of Tgf-β1. The abundance is relative to the input in the same sample with the
same primer. CT or NC, non-injured rats or cells; I/R or H/R, I/R injured rats or H/R injured
cells; I/R or H/R + Ap, apelin-13 treated I/R injured rats or H/R injured cells, n = 3 per
group. ⁎p b 0.05 compared to NC group; #p b 0.05 compared to I/R or H/R group.
Fig. 6. Over-expression of apelin inhibits H/R activated apoptosis and Tgf-β1 in HBZY-1
cells. Representative PCR analysis with densitometric quantitative results of Apln, Rn18s
were shown in (A). RepresentativeWestern blot analysis with densitometric quantitative
results of APJ, Hif1α and β-actin were shown in (B). RepresentativeWestern blot analysis
with densitometric quantitative results of caspase-3 (35 KD), c-cas3 (19 KD), c-cas3 (17
KD), c-cas8 (26KD), c-cas8 (18KD), PARP-1, c-PARP-1 andβ-actinwere shown in (C). Rep-
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treatment signiﬁcantly inhibited the I/R-induced increase in H3K4me2
binding to the promoter of Tgf-β1 in the kidneys (Fig. 5B). Consistent
with the in vivo study, signiﬁcantly increased Tgf-β1 mRNA was also
observed in tubular epithelial cells and mesangial cultured under H/R
conditions, and apelin-13 treatment reduced H/R-induced elevation of
Tgf-β1 (Fig. 5C and D).resentative PCR analysis with densitometric quantitative results of Tgf-β1 and Rn18s are
shown in (D). NC + β-gal, cells transfected with the pPCAGSIH-β-gal plasmid cultured
under normal condition; H/R + β-gal, cells transfected with the pPCAGSIH-β-gal plasmid
cultured under H/R condition; H/R + apelin, cells transfected with the pPCAGSIH-apelin
plasmid cultured under H/R condition, n = 3 per group. *p b 0.05 compared to NC
group; #p b 0.05 compared to H/R + β-gal group.3.6. Over-expression of apelin protects mesangial cells from H/R induced
apoptosis and Tgf-β1 up-regulation
In addition to direct apelin-13 treatment, the pPCAGSIH-apelin plas-
mid was used to study the effects of apelin over-expression in H/R in-
jured mesangial cells. Apln mRNA was signiﬁcantly decreased in H/R
injured cells compared to control cells. Over-expression of apelin mark-
edly up-regulated AplnmRNA level in HBZY-1 cells cultured under H/R
conditions (Fig. 6A). No signiﬁcant difference in APJ level was observed
in HBZY-1 cells cultured under different conditions. Furthermore, over-
expression of apelin signiﬁcantly suppressed H/R-induced increased
Hif1α level in HBZY-1 cells (Fig. 6B).
Caspase-3 has been shown to be primarily responsible for the cleav-
age of poly(ADP-ribose) polymerase-1 (PARP-1) during cell death [46].
Compared to control cells, elevated cell death in H/R stimulated cells
was demonstrated by elevation of the cleaved, active form of caspase-
3, caspase-8 and PARP-1, and these changes were markedly attenuated
by apelin over-expression (Fig. 6C).We next examined whether over-expression of apelin could sup-
press H/R up-regulated Tgf-β1mRNA level in HBZY-1 cells. A signiﬁcant
increase of Tgf-β1mRNA level in HBZY-1 cells after H/R injury was ob-
served, which was markedly suppressed by over-expression of apelin
(Fig. 6D).
3.7. Over-expression of apelin alters histone methylation level in H/R
stimulated HBZY-1 cells
We also analyzed histone methylation in H/R injured HBZY-1 cells
with apelin over-expression. Substantial increases in histone methyla-
tion (H3K4me2 and H3K79me1) was evident in HBZY-1 cells cultured
under H/R conditions compared to controls, whereas this increase was
Fig. 8. Possible mechanisms behind the beneﬁcial effects of apelin on renal I/R injury.
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examined the mRNA levels of Ash1, Kmt2d in HBZY-1 cells cultured
under normal or H/R conditions. Only themRNA level of Kmt2dwas sig-
niﬁcantly increased in HBZY-1 cells cultured under H/R condition com-
pared with control cells, but was markedly reduced in the H/R treated
cells that over-express apelin (Fig. 7C, D).
4. Discussion
The number of AKI patients, as well as the population susceptible to
AKI, such as diabetic and hypertension patients, is increasing world-
wide, whereas an optimal therapy for AKI is still lacking [47,48]. Rodent
renal I/R injury is a good model to study the pathogenesis of AKI and to
seek possible therapies for the disease. A recent report suggested that
administration of apelin-13 or leptin suppresses the renal I/R injury in-
duced elevation of urea and pathological damage in rats [49], however
the underlying mechanism for these beneﬁcial effects remains un-
known. In the present study, we report that apelin-13 signiﬁcantly in-
hibits I/R injury induced renal dysfunction in rats. Furthermore, our
results demonstrate that apelin-13 suppressed inﬂammation (ICAM-1
expression) and apoptosis (caspase-3 activation) in both renal I/R in-
jured rats and renal cells cultured under H/R injury conditions. Thus,
our data suggested that apelin-13 plays a protective role in renal I/R
injury through its anti-apoptotic and anti-inﬂammatory action.
Clinical studies have demonstrated that the level of apelin is signiﬁ-
cantly reduced in kidney allograft recipients with coronary artery dis-
ease and the patients with autosomal dominant polycystic kidney
disease [50]. Consistent with the clinical observations, in the rodent hy-
pertension model induced by two-kidney-one-clip (2K1C), reduced
serum level of apelin but not Ang II and arginine-vasopressin is also ob-
served, accompanied by signiﬁcantly decreased mRNA and protein
levels of APJ in ischemic kidneys [51]. However, administration of
apelin-13 (20 μg/kg) signiﬁcantly decreased systolic and diastolic
blood pressures in these 2K1C-induced hypertensive rats [51]. Further-
more, apelin-13 showed signiﬁcant protective effects on diabetic ne-
phropathy in two different type 1 diabetic mouse models [24,52].Fig. 7. Over-expression of apelin regulates H/R induced histone methylation in HBZY-1
cells. Representative western blot analysis of H3K4me2, H3K79me1 and H3 were shown
in (A), with densitometric quantitative results in (B). Representative PCR analysis of
Ash1, Kmt2d and Rn18s were shown in (C), with densitometric quantitative results in
(D). NC + β-gal, cells transfected with the pPCAGSIH-β-gal plasmid cultured under nor-
mal condition; H/R + β-gal, cells transfected with the pPCAGSIH-β-gal plasmid cultured
under H/R condition; H/R + apelin, cells transfected with the pPCAGSIH-apelin plasmid
cultured under H/R condition, n = 3 per group. *p b 0.05 compared to NC group;
#p b 0.05 compared to H/R + β-gal group.Taken together, including the present ﬁndings, the apelin is a new bio-
marker whose level can predict renal function and apelin-13 appears
to be a good therapeutic candidate for chronic and acute renal diseases,
at least in rodent models.
TGF-β1 has been ﬁrmly established as a central mediator of kidney
ﬁbrosis and inﬂammation associated with progressive kidney diseases
[6,7]. During H/R injury, hypoxia caused by vascular insufﬁciency may
enhance TGF-β1 synthesis [53,54]. Recent studies have suggested that
the crucial role of TGF-β1 in collagen synthesis and ﬁbrosis may be an-
tagonized and/or reduced by the action of certain agents, such as proteo-
glycan decorin or KS370G [55,56],which inhibit TGF-β1 level and exert a
protective effect of kidneys in renal I/R injury [56,57]. In the present
study, administrating apelin-13 or over-expressing apelin both signiﬁ-
cantly suppressed I/R and H/R induced elevated Tgf-β1 in kidneys and
cultured renal cells. Furthermore, apelin-13 treatment also inhibits the
I/R and H/R induced elevated Tgf-β1 in the kidneys and cultured renal
cells. Thus, the anti-apoptotic and anti-inﬂammatory actions of apelin-
13 on renal I/R injury are due to its inhibitory role on Tgf-β1.
In the present study, among the altered histone methylation and
HMTs levels, the elevation of H3K4me2 and upregulation of Kmt2d
was consistently found in I/R injured kidneys and cultured renal cells,
and these I/R induced alterations were markedly inhibited by apelin-
13. KMT2D mutations have been found in the patients with clear-cell
renal cell carcinoma or Kabuki syndrome [58]. Furthermore, KMT2D
mutations in Kabuki syndrome patients are more likely to have kidney
anomalies than those patients without KMT2D mutation [59,60], sug-
gesting dysfuncation or abnormal level of KMT2D may contribute to
the development of renal diseases. In the present study, we also demon-
strated that after renal I/R injury, elevated H3K4me2 bound to the
promoter of Tgf-β1 which lead to increased transcription of Tgf-β1,
and apelin-13 treatment down-regulated Tgf-β1 as well as reduced
H3K4me2 bound to the promoter of Tgf-β1 after renal I/R injury. Further
studies are required to determine whether Kmt2d can directly bind to
the promoter of Tgf-β1 and regulate transcription of Tgf-β1. Through
regulation of histone modiﬁcations and the responsible enzymes,
apelin-13 may transform the action of a short-term elevation of this
adipocytokine into a long-lasting signaling pathway change. However,
the critical role of Kmt2d in renal I/R injury and whether it is the
major target for apelin-induced renoprotection in renal I/R injury awaits
further investigation.
In summary, this study revealed a novel mechanism underlying the
anti-inﬂammatory, anti-apoptotic and anti-ﬁbrotic action of apelin-13,
which confers protection against I/R injury in the kidney by epigenetic
regulation. Either exogenous apelin-13 treatment or endogenous ex-
pression Apln in cultured renal cells also demonstrated the cell death
1286 H. Chen et al. / Biochimica et Biophysica Acta 1852 (2015) 1278–1287protective role of apelin-13 on reducing Tgf-β1 after in vitro H/R injury
(Fig. 8). All these suggest that apelin-13 may be considered as a viable
strategy to prevent acute cell damage and improve the outcome of I/R
injury to the kidneys.
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